T6654
チクロピジン 塩酸塩
analytical standard, for drug analysis
別名:
5-(o-クロロベンジル)-4,5,6,7-テトラヒドロチエノ(3,2-c)ピリジン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H14ClNS · HCl
CAS番号:
分子量:
300.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
258-837-4
MDL number:
製品名
チクロピジン 塩酸塩, analytical standard, for drug analysis
InChI key
MTKNGOHFNXIVOS-UHFFFAOYSA-N
InChI
1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H
SMILES string
Cl.Clc1ccccc1CN2CCc3sccc3C2
assay
≥99%
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
Quality Level
Gene Information
human ... P2RY12(64805)
類似した製品をお探しですか？ 訪問 製品比較ガイド
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Ticlopidine hydrochloride has been used as an analytical standard to investigate the developmental toxicity and teratogenic potential of ticlopidine in Xenopus laevis embryos and human endothelial cells using a frog embryo teratogenesis assay-Xenopus (FETAX) and blood and lymph vessel formation assay.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
T6654-BULK: + T6654-VAR: + T6654-25G: + T6654-5G: + T6654-1G:
jan
Characterization of ticlopidine-induced developmental and teratogenic defects in Xenopus embryos and human endothelial cells.
Park SM, et al.
Chemico-Biological Interactions, 240, 172-178 (2015)
Peter Damman et al.
The American journal of cardiology, 113(1), 64-69 (2013-10-31)
Large real-world registry data are important for understanding the current use and outcomes of novel therapies. The aim of this study was to assess treatment patterns and outcomes in patients who underwent percutaneous coronary intervention (PCI) with prasugrel or clopidogrel.
Thomas O Bergmeijer et al.
American heart journal, 168(1), 16-22 (2014-06-24)
In patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (pPCI), the use of dual antiplatelet therapy is essential to prevent atherothrombotic complications. Therefore, patients are treated with acetylsalicylic acid and clopidogrel, prasugrel, or ticagrelor. Clopidogrel
Colin P Derdeyn et al.
Lancet (London, England), 383(9914), 333-341 (2013-10-31)
Early results of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis trial showed that, by 30 days, 33 (14·7%) of 224 patients in the stenting group and 13 (5·8%) of 227 patients in the medical
Jan H Cornel et al.
American heart journal, 168(1), 76-87 (2014-06-24)
To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）